Filter Results
Filter Results
Filter by Offering
Integrated Biologics Advanced Synthesis Small Molecules Cell & Gene Specialized Modalities Capsules & Health Ingredients Corporate Drug Product Services Licensing Mammalian
Mammalian (95) Expression Technologies (61) Autologous (42) Parenteral Drug Product (41) Viral Vectors (41) Allogeneic (38) iPSCs (32) Microbial (21) Bioconjugates/ADC (17) Exosomes (17) mRNA (13)
Oral Drug Products (86) Bioavailability Enhancement (78) Monoclonal Antibody (72) Drug Substance (API/HPAPI) (62) Bispecific Antibody (56) Particle Engineering (46) Difficult to Express Proteins (40) Inhalation (32) Antibody Drug Conjugates (26) Fabs, Fusion, Scaffold and other Recombinant Proteins (21) Enhanced ADCC (12) Solid Form Services (11) Injectables (5) Lipid Nanoparticle Encapsulation (4) Drug device combinations (1)
Formulation Development and Optimization (81) Process Development and Optimization (70) Analytical Development (56) Cell Line Development (52) Clinical Supply Services (51) Manufacturing: cGMP (51) First-in-Human Services (50) Early De-risking & Optimization (38) API Services (36) Manufacturing: GMP Drug Substance (35) Commercial Supply Services (34) Regulatory Services (32) Manufacturing: GMP Drug Product (20) IND-to-BLA (18) Viral Vector Expression Technologies (14) Bispecific DNA-to-IND (12) Parenteral Drug Product Development (11) Immunogenicity Assessment (10) mAb DNA-to-IND: Ibex® Design (10) PBPK Modeling (8) Strain Development (6) Tissue Acquisition (6) Antibody Humanization & Deimmunization (5) Solid Form Services (5) Tech Transfer (4) Ibex® Dedicate (3) Manufacturing: Non-GMP Manufacture (3) Fabs and Fc-Fusion proteins DNA-to-IND (1) Scaffolds and Other Recombinant Proteins DNA-to-IND (1) Special Analytical Services (1)
Mammalian Expression Technologies (56) Spray Dried Dispersions (52) GS Xceed® Gene Expression System (41) GS Gene Expression System® (39) GS piggyBac® Transposon System (35) Hot Melt Extrusion (27) Particle Size Reduction (27) Cocoon® Platform (23) GSquad® Vectors (22) Microbial Expression Technologies (19) Technology Selection (18) Micronization (16) Micro-dosing/Powder-in-capsule (14) Viral Vector Expression Technologies (14) bYlok™ Bispecific Antibodies Technology (13) GS Effex® (12) Taste-masking and Multiparticulates (12) GS Discovery® (9) Modified and Delayed Release (9) XS Technologies® (7) 4D-Nucleofector LV (5) MODA® (5) LNP (4)
Webinar (on-demand) (124) White paper (93) Article (63) Peer-reviewed publication (44) Technical/Service brief (37) Podcast (30) Presentation (on-demand) (29) Poster (25) R&D Blog post (22) Video (17) e-book (15) Presentation (slides) (13) CDMO Notes Blog post (5) Interview (5) Report (1)
Reset Filters
   Loading...
Showing 57‐84 of 500
Technical/Service brief
GMP Tissue Sourcing
A complex process, prone to misconceptions and pitfalls, to find the “right human tissue” that will yield the desired cell quality and quantity, and pass BLA approval. Download our infographic to learn more
Article
10 min read
The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress
With a long standing track record of success, GS-CHO based expression systems have become the most widely used platform for developing and manufacturing recombinant therapeutic proteins today. But the evolving demands of the biologics industry including p...
Webinar (on-demand)
Extracellular Vesicles - Setting-Up the Path to IND With Advanced Characterization Packages
Abstract: During this webinar, our expert will share insights on how precise analytics and process design can ensure your extracellular vesicle (EV) therapies succeed in clinical development. Key learning points: - Why characterization is the cornerstone ...
Technical/Service brief
End-To-End Production of T Cells on the Cocoon® Platform, Using Buoyancy-Activated Cell Sorting™ For T Cell Isolation From Leukopaks
Performance data of the Cocoon® Platform using Buoyancy-Activated Cell Sorting™ for T cell isolation from leukopaks: isolation of T cells directly from cryopreserved leukopaks: - No additional upstream equipment required - Reduced operator interactions - ...
Article
6 min read
mRNA Research Services to Accelerate Your Project
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic.[1] Longer synthetic pathways make it more difficult for process chemists to achieve ...
e-book
15 min read
Navigating Commercial Drug Development Technologies for Formulation Excellence
Our Small Molecule division is focused on leveraging its technologies and expertise to address solubility challenges and support drug development programs through commercialization. Download our e-book to learn about the importance of patient-centric form...
Article
8 min read
Understanding Glycosylation in Antibodies
Proteins often undergo a variety of post-translational modifications (PTMs) after their initial synthesis, including phosphorylation, methylation, acetylation, and glycosylation, among others. These modifications are essential for regulating a protein’s f...
Article
10 min read
Meet Your Lentiviral Vector Development and Supply Requirements with Xcite® Lenti, an Optimized Suspension-Based Platform Technology
Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising significantly, creating a need for robust, highly productive and scalable manufacturing processes. Lonza’s ready-to-use, suspension-based Xcite® Lenti Platform Technolo...
White paper
20 min read
Powering Drug Development with Advanced Retrosynthetic Analysis Tools
As small molecule APIs become increasingly complex, longer synthetic pathways present new challenges for process chemists. Drug developers are turning to evolving tools to find reliable and efficient synthesis routes to produce small molecule APIs. This w...
White paper
7 min read
Science of Scale for Spray-Dried Intermediates
Speed to market is a critical aspect of developing new pharmaceutical products, and scale-up-or scale-down-can play a key part in that process. Significant interest has been focused on the science of scale for spray drying, since this process is the leadi...
White paper
18 min read
Lonza as Your Lifecycle Partner for End-to-End Bioconjugate Drug Development
Due to the complicated nature of and expense behind developing and manufacturing antibody drug conjugates (ADCs), around 70% of ADC developers rely on the support of contract development and manufacturing organizations (CDMOs). It is, therefore, vital to ...
Webinar (on-demand)
AAV Transient Transfection and Producer Cell Line Platforms to Accelerate your Path to IND
Abstract: During this webinar, our experts will share insights on how our cutting-edge AAV transient transfection and producer cell line platforms can significantly accelerate your journey towards Investigational New Drug (IND) application success. Curren...
R&D Blog post
4 min read
Better, Faster Pharma Manufacturing with Lonza’s AI Route Design
Overcoming the complexities of pharmaceutical manufacturing through Lonza's combined expertise and the power of AI.
Article
10 min read
Making More Effective Antibody-Based Immunotherapies with the GS Effex® Cell Line
Antibody-based immunotherapies can mediate cancer cell death via multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). The level of ADCC activity has been shown to have a direct impact on their potency. One of the most effective ...
Interview
3 min read
Q&A: How bYlok® Technology Improves Bispecific Antibody Development
Q&A with a Lonza expert about how bYlok® technology can help improve bsAb development.
Webinar (on-demand)
60 min read
Navigating Your Holistic Approach to Container Closure Integrity for Biologic Drug Products
A tightly closed container is a prerequisite for aseptically filled parenteral drug products to be safe. Therefore, regulatory authorities expect demonstration that Container closure integrity (CCI) is maintained throughout product shelf life. Good practi...
Technical/Service brief
5 min read
The Early Advantage for mRNA
Our mRNA research services offer you an easy approach to simplify and accelerate your mRNA/LNP project. Learn more today about our early development services for mRNA and its encapsulation in lipid nanoparticles (LNPs).
Webinar (on-demand)
Risk Based Development to Support Process Qualification for Spray Dried Dispersions
This session delves into a risk-based approach for supporting process qualification of amorphous solid dispersions produced by spray drying. Our expert speakers discuss the integration of process design and qualification into the broader process validatio...
Webinar (on-demand)
Balancing the Scales: The Ups and Downs of Bioprocess Scale-up
Scale-up is typically seen as a technical challenge. While this is true, the partnership with our customers requires us to align on the scientific imperatives as well as the needs of two businesses. In this webinar, Sven Bieli shares his technical and com...
Technical/Service brief
5 min read
AI-Enabled Route Scouting Service Technical Brief
Small molecule active pharmaceutical ingredients (APIs) are becoming more molecularly complex, resulting in formidable challenges for small and emerging biotechs. Lonza’s AI-Enabled Route Scouting Service is an advanced approach to retrosynthetic analysis...
Webinar (on-demand)
Dry Powder Inhalable Vaccines for Shelf Stability and Global Access
What if a formulation were possible that removed the need for cold chain distribution? There is a significant need for shelf-stable vaccines that are simpler to store and distribute. Vaccines require cold chain distribution and to be stored in a refrigera...
Webinar (on-demand)
Innovative Analytical Strategies to Address Common Challenges in the Development of New Molecular Formats; Focusing on BLA: Process Characterization
Today's biopharmaceutical landscape is seeing a rise in complex next-generation biological molecules. These molecules, with their intricate structures and variations compared to traditional antibody formats, present unique challenges for manufacturers. Th...
Webinar (on-demand)
Optimizing the Path to First-in-Human Clinical Trials: An Integrated Approach to Design and De-risk Your Candidate
In early drug development, optimizing your path to first-in-human clinical trials is critical to ensure the most efficient use of limited resources and tight timelines. However, a large portion of biologics fail during development due to issues with effic...
Technical/Service brief
4 min read
Lonza’s Microbial Capabilities Expanded by New 2x 4,000L Microbial Fermentation Capacity
It’s a wise approach, to partner with a CDMO that has flexible capacity solutions and offers fully integrated services from development lab to regulatory filing. Considering this in your CMC strategy, provides the flexibility to react to variation in your...
CDMO Notes Blog post
6 min read
Advanced Genetic Analysis & The Future of Next-Generation Sequencing
Dr. Neil Taylor explains Lonza’s approach to advanced genetic analysis - from new technologies to driving the future of next gen sequencing.
CDMO Notes Blog post
6 min read
Unlocking Efficiency in Biologics Manufacturing with a Novel Process Intensification Platform
Dr. Ruth Rowland-Jones explains how Lonza is revolutionizing biologics with new Process Analytics Technologies (PAT) to drive global change.
Presentation (on-demand)
27 min read
Solutions for High Titre Expression of Cancer Immunotherapies
Biological pipelines for oncology indications are evolving, with next-generation molecules joining more traditional monoclonal antibodies. These advances increase pressure on cell line construction timelines and create challenges in identifying cell lines...